287 related articles for article (PubMed ID: 31542876)
21. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer.
Cespedes Feliciano EM; Kwan ML; Kushi LH; Chen WY; Weltzien EK; Castillo AL; Sweeney C; Bernard PS; Caan BJ
Cancer; 2017 Jul; 123(13):2535-2542. PubMed ID: 28295245
[TBL] [Abstract][Full Text] [Related]
22. PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study.
Phakathi B; Dix-Peek T; Van Den Berg E; Dickens C; Nietz S; Cubasch H; Joffe M; Neugut AI; Jacobson JS; Ruff P; Duarte R
Breast Cancer Res Treat; 2023 Aug; 200(3):337-346. PubMed ID: 37266756
[TBL] [Abstract][Full Text] [Related]
23. Stratification of Breast Cancer by Integrating Gene Expression Data and Clinical Variables.
He Z; Zhang J; Yuan X; Xi J; Liu Z; Zhang Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30754661
[TBL] [Abstract][Full Text] [Related]
24. Translating Research into Practice: the Prosigna® (PAM50) Gene Signature Assay.
Boccia RV
Clin Adv Hematol Oncol; 2015 Jun; 13(6 Suppl 6):3-13. PubMed ID: 26191941
[TBL] [Abstract][Full Text] [Related]
25. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Liu S; Chapman JA; Burnell MJ; Levine MN; Pritchard KI; Whelan TJ; Rugo HS; Albain KS; Perez EA; Virk S; Barry G; Gao D; O'Brien P; Shepherd LE; Nielsen TO; Gelmon KA
Breast Cancer Res Treat; 2015 Jan; 149(2):439-48. PubMed ID: 25552364
[TBL] [Abstract][Full Text] [Related]
27. Increased RNA Expression of von Willebrand Factor Gene Is Associated With Infiltrating Lobular Breast Cancer and Normal PAM50 Subtype.
Lehrer S; Green S; Dembitzer FR; Rheinstein PH; Rosenzweig KE
Cancer Genomics Proteomics; 2019; 16(3):147-153. PubMed ID: 31018945
[TBL] [Abstract][Full Text] [Related]
28. Prediction consistency and clinical presentations of breast cancer molecular subtypes for Han Chinese population.
Huang CC; Tu SH; Lien HH; Jeng JY; Liu JS; Huang CS; Wu YY; Liu CY; Lai LC; Chuang EY
J Transl Med; 2012 Sep; 10 Suppl 1(Suppl 1):S10. PubMed ID: 23046482
[TBL] [Abstract][Full Text] [Related]
29. Superior breast cancer metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene signature.
Emad A; Ray T; Jensen TW; Parat M; Natrajan R; Sinha S; Ray PS
Breast Cancer Res; 2020 Jul; 22(1):74. PubMed ID: 32641077
[TBL] [Abstract][Full Text] [Related]
30. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
Lundberg A; Lindström LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Breast Cancer Res; 2019 Feb; 21(1):34. PubMed ID: 30819233
[TBL] [Abstract][Full Text] [Related]
31. Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes.
Liu R; Zhang W; Liu ZQ; Zhou HH
Oncotarget; 2016 Apr; 7(16):21686-98. PubMed ID: 26934123
[TBL] [Abstract][Full Text] [Related]
32. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
[TBL] [Abstract][Full Text] [Related]
33. Identification of a New Eight-Long Noncoding RNA Molecular Signature for Breast Cancer Survival Prediction.
Zhang Y; Li Z; Chen M; Chen H; Zhong Q; Liang L; Li B
DNA Cell Biol; 2019 Dec; 38(12):1529-1539. PubMed ID: 31647329
[TBL] [Abstract][Full Text] [Related]
34. miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study.
Natarajan L; Pu M; Davies SR; Vickery TL; Nelson SH; Pittman E; Parker BA; Ellis MJ; Flatt SW; Mardis ER; Marinac CR; Pierce JP; Messer K
Cancer Epidemiol Biomarkers Prev; 2019 Sep; 28(9):1525-1533. PubMed ID: 31186261
[TBL] [Abstract][Full Text] [Related]
35. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Filipits M; Nielsen TO; Rudas M; Greil R; Stöger H; Jakesz R; Bago-Horvath Z; Dietze O; Regitnig P; Gruber-Rossipal C; Müller-Holzner E; Singer CF; Mlineritsch B; Dubsky P; Bauernhofer T; Hubalek M; Knauer M; Trapl H; Fesl C; Schaper C; Ferree S; Liu S; Cowens JW; Gnant M;
Clin Cancer Res; 2014 Mar; 20(5):1298-305. PubMed ID: 24520097
[TBL] [Abstract][Full Text] [Related]
36. RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer.
Lang JE; Ring A; Porras T; Kaur P; Forte VA; Mineyev N; Tripathy D; Press MF; Campo D
Ann Surg Oncol; 2018 Aug; 25(8):2261-2270. PubMed ID: 29868978
[TBL] [Abstract][Full Text] [Related]
37. Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes.
Ye IC; Fertig EJ; DiGiacomo JW; Considine M; Godet I; Gilkes DM
Mol Cancer Res; 2018 Dec; 16(12):1889-1901. PubMed ID: 30037853
[TBL] [Abstract][Full Text] [Related]
38. Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.
Kimbung S; Kovács A; Danielsson A; Bendahl PO; Lövgren K; Frostvik Stolt M; Tobin NP; Lindström L; Bergh J; Einbeigi Z; Fernö M; Hatschek T; Hedenfalk I
Oncotarget; 2015 Oct; 6(32):33306-18. PubMed ID: 26375671
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
[TBL] [Abstract][Full Text] [Related]
40. A comparative study of PCS and PAM50 prostate cancer classification schemes.
Yoon J; Kim M; Posadas EM; Freedland SJ; Liu Y; Davicioni E; Den RB; Trock BJ; Karnes RJ; Klein EA; Freeman MR; You S
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):733-742. PubMed ID: 33531653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
